MedTrace Logo

A Study to Test How Well Healthy Men and Women Tolerate Different Doses of BI 706321

NCT04241458 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-08-24

Study results available
· View outcomes & findings →

Summary

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 706321 in healthy male and female subjects following oral administration of multiple rising doses for 14 days.

Conditions

  • Healthy

Interventions

DRUG

BI 703621

BI 703621

DRUG

Placebo

Placebo

DRUG

Midazolam

Midazolam

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-30
Primary Completion
2020-11-24
Completion
2020-11-24

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04241458 on ClinicalTrials.gov